Advocacy intelligence hub — real-time data for patient organizations
Marcela V. Maus, M.D.,Ph.D. — PHASE2
Mayo Clinic — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Kymriah
(tisagenlecleucel)Orphan drugstandardNovartis Pharmaceuticals Corporation
CD19-directed Chimeric Antigen Receptor [EPC]
12.1 Mechanism of Action KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy which involves reprogramming a patient’s own ...
Zynlonta
(loncastuximab tesirine-lpyl)Orphan drugacceleratedADC Therapeutics SA
12.1 Mechanism of Action Loncastuximab tesirine-lpyl is an antibody-drug conjugate (ADC) targeting CD19. The monoclonal IgG1 kappa antibody component ...
Stephen M Ansell, M.D
Dana-Farber - Harvard Cancer Center LAO
📍 ROCHESTER, MN
Premal Lulla, MD, M.D
Baylor College of Medicine
📍 HOUSTON, TX
Stephen M. Ansell, MD, PhD, M.D
Mayo Clinic in Rochester
📍 ROCHESTER, MN
Claire Tiger, MD, PhD, M.D
Mayo Clinic
📍 ROCHESTER, MN
Frank G Basile, M.D., MD
Schrodinger Inc.
📍 RIVERSIDE, RI
Matthew Frigault, MD
Massachusetts General Hospital
📍 Boston, Massachusetts